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Intra-articular gene therapy has potential for the treatment of osteoarthritis and rheumatoid arthritis. To quantify in vitro relative
gene transduction, equine chondrocytes and synovial cells were treated with adenovirus vectors (Ad), serotype 2 adeno-associated
virusvectors(rAAV2),orself-complementary(sc)AAV2vectorscarryinggreenﬂuorescentprotein(GFP).Using6horses,bilateral
metacarpophalangeal joints were injected with Ad, rAAV2, or scAAV2 vectors carrying GFP genes to assess the in vivo joint
inﬂammation and neutralizing antibody (NAb) titer in serum and joint ﬂuid. In vitro, the greater transduction eﬃciency and
sustained gene expression were achieved by scAAV2 compared to rAAV2 in equine chondrocytes and synovial cells. In vivo, AAV2
demonstrated less joint inﬂammation than Ad, but similar NAb titer. The scAAV2 vectors can induce superior gene transduction
than rAAV2 in articular cells, and both rAAV2 and scAAV2 vectors were showed to be safer for intra-articular use than Ad vectors.
1.Introduction
In elderly people, joint disorders including osteoarthritis and
rheumatoid arthritis remain major causes of mobility loss
[1]. Gene therapy has a great potential for the treatment of
these conditions by using intra-articular gene delivery, such
as previously described for interleukin-1 receptor antagonist
(IL-1Ra) [2, 3], transforming growth factor-β1[ 4], or tum-
ournecrosisfactoralphaantagonistprotein[5].Directintra-
articular administration of gene delivery vectors is an attrac-
tive and eﬀective strategy to transduce articular cartilage and
synovium with therapeutic genes, because joints are discrete
and accessible cavities that can be easily injected [6].
A choice of viral vectors has been used to introduce ther-
apeutic genes to intra- and periarticular tissues including ad-
enovirus (Ad) [7, 8] and serotype 2 adeno-associated virus
(AAV2) [9–11], and Ad vectors have been shown to induce
rapidandsuccessfultransgeneexpression,butintra-articular
usage has been restricted due to robust inﬂammatory and
immune reactions, as well as limited by transient transgene
expression [6–8]. In contrast, recombinant AAV2 (rAAV2)
has gained much attention as a safer vector for gene delivery
to joints, because it can induce sustained transgene expres-
sion in the absence of signiﬁcant inﬂammation [6, 9–11].
In addition, rAAV2-mediated joint therapy may be advan-
tageous by its greater penetration into articular cartilage,
likely due to smaller particle size [12]. Moreover, AAV2
vectors have been modiﬁed to package self-complementary
DNA, capable of bypassing the rate-limiting step of second-
strandsynthesisin ordertoaccelerateandimprove the trans-
duction eﬃciency [12, 13]. Such self-complementary AAV2
(scAAV2) vectors have been shown to eﬀectively transduce
chondrocytes and synovial cells [14] and cartilage explants
[12] in vitro, and induce superior transgene expression in
cartilage and synovium tissues after injection of 5 × 1011
particles in vivo in rodent models [3]. Taken together, intra-
articular administration of scAAV2 vectors has potential
for future clinical application, but the inﬂammation and2 Arthritis
immune reactions, cell tropism, and application to larger
joints as in people have not been directly compared among
rAAV2, scAAV2, or Ad vectors in vivo.
Theobjectivesofourstudyweretoassesstherelativegene
transduction and duration of expression among Ad, rAAV2,
andscAAV2vectorscarryinggreenﬂuorescentprotein(GFP)
in chondrocytes and synovial cells in vitro and compare
the inﬂammation and immune response by the intra-articu-
lar administration of Ad, rAAV2, and scAAV2 vectors in vivo
in equine joints of similar size to human joints. We hypo-
thesized that scAAV2 vectors would show accelerated and
greater gene transduction in vitro compared to rAAV2 and
inducelessinﬂammationandimmuneresponseinvivocom-
pared to Ad vectors.
2.MaterialsandMethods
2.1. Viral Vector Production. Recombinant E-1 deleted hu-
manserotype5adenoviruspreparations,single-strandedhu-
man serotype 2 AAV2, and scAAV2 containing GFP under
the control of the cytomegalovirus (CMV) promoter were
generated and puriﬁed by cesium chloride density gradient
method[12,15].ParticlecountofAdvectorswasdetermined
by optical density at 260nm, and particle titers of rAAV2 and
scAAV2 vectors were determined by DNase-resistant parti-
cle (DRP) values using real-time PCR assay as described pre-
viously [16].
2.2. In Vitro Experimental Design and Vector Administration.
Articular cartilage and synovium were harvested from the
tarsocrural joints of 6 healthy adult horses immediately after
euthanasia. Chondrocytes and synovial cells were isolated by
type I collagenase tissue digestion for 8 hours and cultured
in DMEM supplemented with L-glutamine (300μg/mL),
penicillin (30μg/mL), streptomycin (30μg/mL), and 10%
fetal bovine serum at 37◦Ci na5 %C O 2 atmosphere [17].
After expanding for 3–5 passages, the equine chondrocytes
and synovial cells were placed in 48-well plates at a density
of 10,000 cells/well (day 1). Twenty-four hours later (day
0), the DMEM was aspirated, and the duplicate wells were
treated with 200μL of Gey’s balanced salt solution (GBSS)
containing Ad-GFP at 1 × 102,1× 103,o r1× 104 parti-
cles/cell (1 × 106,1× 107,o r1× 108 particles/well, resp.),
or rAAV2-GFP, or scAAV2-GFP at 1 × 104,1× 105,o r1×
106 DRP/cell (1 × 108,1× 109,o r1× 1010 DRP/well, resp.).
After 2-hour incubation at 37◦Ci na5 %C O 2 atmosphere,
the GBSS was aspirated and replaced with 1mL DMEM. The
chondrocytesandsynovialcellswereculturedfor6weeks(42
days), while the DMEM were changed at days 7, 14, 17, 21,
24, 28, 30, 32, 35, 37, 39, and 42.
2.3. In Vitro Gene Transduction. Transduction of the Ad-
GFP, rAAV2-GFP, or scAAV2-GFP-treated cells was deter-
mined by the ratio of GFP-expressing cells to the total num-
ber of cells observed via ﬂuorescent microscopy within the
5ﬁ e l d so f2 5× 25-μm area under 200x magniﬁcation [17].
The % transduction was assessed at days 2, 7, 10, 14, 17, 21,
24, 28, 31, 35, 38, and 42. The % transduction values from
the duplicate culture wells were averaged.
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Figure 1: In vivo experimental design of intra-articular admin-
istration of adenoviral (Ad), recombinant aden-associated viral
(rAAV2), or self-complementary AAV (scAAV2) vectors containing
green ﬂuorescent protein (GFP).
2.4. In Vivo Experimental Design and Vector Administration.
T h ei nv i v oe x p e r i m e n t a ld e s i g ni ss u m m a r i z e di nFigure 1.
AllprocedureswereapprovedbytheInstitutionalLaboratory
Animal Care and Use Committee at The Ohio State Univer-
sity.
By using 4 healthy adult horses (3 Thoroughbreds and 1
Quarter horses) aged 5–12 years (median age: 7) and weight
418–536kg (mean weight: 429kg), 8 metacarpophalangeal
joints (2 joints/horse) were treated by the intra-articular
administration of GBSS, Ad-GFP (5 × 1011 particles/joint),
rAAV2-GFP (5 × 1011 DRP/joint), scAAV2-GFP (5 ×
1011 DRP/joint), or scGFP (1 × 1013 DRP/joint). In joints
assigned randomly to be injected with Ad, GBSS was injected
at day 0 and the Ad-GFP at day 14 after a normalization
p e r i o d ,b e c a u s eA dv e c t o r sw e r ee x p e c t e dt oi n d u c er a p i d
transgene expression. The GBSS-induced inﬂammation was
assessed between day 0 and 14 prior to the Adinjection.
Intra-articular administration of viral vectors was per-
formedwhilehorses werestanding and sedated withxylazine
hydrochloride(i.v.,1mg/kg).Aftertheasepticpreparationof
skin over the lateral aspect of the metacarpo/tarsophalangeal
joints, the limb was held oﬀ the ground at approximately 120
degree ﬂexion, and a 20G 1.5 inch needle was inserted into
the joint space between the proximal sesamoid bone and
lateral distal condyle of the third metacarpal/tarsal bone by
passing through the lateral collateral sesamoidean ligament.
The intra-articular administrations of assigned treatments
were performed only after the 2mL joint ﬂuid was collected
to ensure the needle placement.
2.5. In Vivo Inﬂammatory and Immune Response. Physical
examinationswereperformedweeklyafterthejointinjection
by evaluating circumference of the injected joints and pain-
free range of joint motion. Circumference of the injected
joint was recorded as the mean of 3 measurements obtained
over the injection site by use of a cloth measuring tape [18].
Range of pain-free motion was recorded as the mean of 3
goniometer measurements of the ﬂexed joint immediatelyArthritis 3
before elicitation of an aversion response such as lifting of
the head or movement of the limb forward/backward [18].
Lameness grades were assigned to each horse by an experi-
enced equine clinician (ALB) using the American Associa-
tion of Equine Practitioners’ lameness with 0.5 increments
[19], whereas a joint on the nonlame limb was assigned as 0
lameness grade.
Joint ﬂuid samples were collected weekly by using the
same technique described above and analyzed for cell count
and total protein concentration. The interleukin 1 beta (IL-
1β) and IL-1Ra protein concentration in the joint ﬂuid
was quantiﬁed by ELISA (Equine IL-1Ra DuoSet, R&D
Systems, Minneapolis, MN). Serum samples were collected
weekly, and neutralizing antibody (NAb) titer for Ad and
AAV2-vectors were measured for serum and joint ﬂuid
samples from all joints. Titers were determined by analyzing
the ability of serum antibody to inhibit Ad-GFP (1 ×
104 particles/cell) or rAAV2/scAAV2-GFP infection (1 ×
106 DRP/cell) on Human carcinoma cells (HeLa cells: 5 ×
103 cells/well in 96-well plates) at 48 hours [15]. By applying
twofold dilution series of sample serum, the NAb titer was
calculated as the highest serum dilution inhibiting Ad or
r A A V 2o rs c A A V 2 - G F Pt r a n s d u c t i o nb y>50%.
2.6. Statistical Analysis. Repeated-measure analysis of vari-
ance (ANOVA) (SAS Institute Inc., Cary, NC) was used to
evaluate the eﬀects of Ad or rAAV2 or scAAV2-mediated
GFP gene delivery with the posttest multiple comparisons
between the treatment groups at each time point using
Proc Mixed statistical models for continuous outcomes and
Genmod statistical models for categorical outcomes. Signif-
icance level was set at P<0.05 for all analyses.
3. Results
3.1. In Vitro Gene Transduction. Self-complementary AAV2
vectorsproducedgreaterandmorerapidGFPgenetransduc-
tion (Figures 2(a) and 2(b)) compared to rAAV2 vectors in
equine chondrocytes and synovial cells. Also, scAAV2 vectors
showed more sustained GFP gene transduction (Figures 2(a)
and 2(b)) compared to Ad vectors when they showed com-
parable % transduction in equine chondrocytes and synovial
cells, where the onset of GFP gene transduction (Figures 2(a)
and 2(b)) was equally rapid to Ad vectors.
3.2. In Vivo Inﬂammatory and Immune Response. The Ad
vectors induced greater articular inﬂammation compared to
rAAV2 and scAAV2 vectors with signiﬁcantly greater joint
ﬂuid cell counts (P<0.03: Figure 3(b)), joint circumference
(P<0.04: Figure 3(c)), and reduced range of joint motion
(P<0.02: Figure 3(d)), joint ﬂuid IL-1β concentration
(P<0.001: Figure 3(e)), and lameness grade (P<0.04:
Figure 3(f)), although all parameters were recovered to
normal values within 4-5 weeks. For the rAAV2- or scAAV2-
injected joints, inﬂammatory parameters were increased, but
not signiﬁcantly diﬀerent than GBSS-injected joints, except
a signiﬁcantly greater joint ﬂuid protein concentration at
day 2 (Figure 3(a)). None of inﬂammatory parameters were
signiﬁcantly diﬀerent between GBSS and rAAV2 or scAAV2
at low dose, and scAAV2 at high dose. None of joint ﬂuid
samples from Ad/AAV2-injected joints showed detectable
concentration of IL-1Ra protein.
The NAb titers against Ad- or AAV2 were signiﬁcantly
greater in the Ad- or AAV2-injected joint ﬂuid compared to
the serum or uninjected contralateral joint ﬂuid (P<0.03:
Figures 4(a) and 4(b)), and injected synovial ﬂuid titers
remained high (>100) to the end of study period. The NAb
titers for both serum and uninjected contralateral joint ﬂuid
against Ad or AAV2 peaked earlier at 2 weeks after intra-
articular administration compared to injected synovial ﬂuid
(Figures 4(a) and 4(b)).
4. Discussion
Self-complementary AAV2 vectors showed promising and
superior eﬃcacy in vitro. Equine chondrocytes and synovial
cells showed greater, more rapid, and sustained gene trans-
duction by scAAV2 vectors compared to rAAV2 (Figures
2(a) and 2(b)). As the result, even 100 times lower dosage
of scAAV2-GFP vectors (1 × 104 DRP/cell) was able to
induce the approximately equal % transduction to rAAV2-
GFP vectors (1 × 106 DRP/cell) in equine chondrocytes
(Figure 2(b)). Bypassing rate-limiting second-strand DNA
synthesis is expected to be largely beneﬁcial to transfect the
certain types of cells with low DNA replication; therefore,
u s eo fs c A A V 2v e c t o rm a yb eg r e a t l ya d v a n t a g e o u sf o ra n
intra-articular administration due to the low cell division
rate of chondrocytes [14]. Because scAAV vectors do not
require the second-strand DNA synthesis step, more rapid
and superior gene expression of scAAV over rAAV vectors
is expected in human chondrocytes and synovial cells as
well. Our study also showed that, for the ﬁrst time, there
were no signiﬁcant diﬀerences in the inﬂammation and
immune response between the intra-articular rAAV2 and
scAAV2 vectors (Figures 3(a) to 3(f) and Figure 4(b)). This
is an expected result because the rAAV2 and scAAV2 vectors
used in this study were the same serotype and contained
the same capsid proteins, where the innate and adaptive
immune responses are primarily initiated by recognition
of the capsid proteins [20, 21]. An advantage of scAAV2
vectors may be detected in humans that have NAb titer
against wild-type AAV2 (80% of human population) in that
l o w e rv e c t o rd o s a g em a yb ee ﬀective and incite less immune
reaction. Previous studies showed that, while the preexisting
immunity by host exposure of the wild-type AAV2 is a
signiﬁcant limiting factor for rAAV2 gene transfer, the
humoral immunity to the AAV2 capsid could be prevented
by lowering the AAV2 particles administered [22].
Our study showed that AAV2 vectors may be a safer
vector of choice for intra-articular gene administration, as
they induced signiﬁcantly less inﬂammatory response in the
joints than Ad vector (Figure 3). The inﬂammation shown in
the Ad-injected joints was expected and was transient. The
signs of swelling, pain, and increased joint ﬂuid protein and
cell counts were signiﬁcantly greater in Ad vectors compared
to rAAV2 or scAAV2 vectors. Importantly, all parameters
were returned to normal values within 4-5 weeks (Figure 3).
Our results support that the adverse eﬀects associated with4 Arthritis
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Figure 2: In vitro gene transduction eﬃciency in equine chondrocytes and synovial cells transfected by adenoviral (Ad), recombinant
adeno-associated viral (rAAV2), or self-complementary AAV (scAAV2) vectors carrying green ﬂuorescent protein (GFP) genes at three
diﬀerent dosages; low, medium, and high dosage levels for Ad-GFP were 1e4, 1e5, and 1e6 particles per cell, and low, medium, and high
dosage levels for rAAV2/scAAV2 were 1e6, 1e7, and 1e8 DRP per cell. (a) Representative ﬂuorescent microscopic images (approximately
90% cell conﬂuence at day 7, and 100% cell conﬂuence at day 14 and 28) and (b) the computed %transduction of equine chondrocytes and
synovial cells. ∗Signiﬁcantly greater gene transduction in same dosage level compared to Ad and rAAV2 vectors. +Signiﬁcantly greater gene
transduction in same dosage level compared to Ad vectors. #Signiﬁcantly greater gene transduction in same dosage level compared to rAAV2
vectors.Arthritis 5
J
o
i
n
t
 
ﬂ
u
i
d
 
t
o
t
a
l
 
p
r
o
t
e
i
n
 
(
g
/
d
L
)
4
3.5
3
2.5
2
0 7 14 21 28 35 42 49 56
Postinjection days
(a)
8000
7000
6000
5000
4000
3000
2000
1000
0
0 7 14 21 28 35 42 49 56
Postinjection days
J
o
i
n
t
 
ﬂ
u
i
d
 
W
B
C
 
c
o
u
n
t
 
(
W
B
C
/
μ
L
)
∗
∗
∗
∗ ∗
∗
∗
∗
∗ ∗
(b)
J
o
i
n
t
 
c
i
r
c
u
m
f
e
r
e
n
c
e
 
(
c
h
a
n
g
e
(
%
)
)
0 7 14 21 28 35 42 49 56
Postinjection days
108
106
104
102
100
98
∗
(c)
∗
∗
∗
∗
125
115
110
105
100
95
0 7 14 21 28 35 42 49 56
Postinjection days
R
a
n
g
e
 
o
f
 
j
o
i
n
t
 
m
o
t
i
o
n
 
(
c
h
a
n
g
e
(
%
)
)
120
(d)
∗ ∗
10
8
6
4
2
0
0 7 14 21 28 35 42 49 56
Postinjection days
J
o
i
n
t
 
f
u
i
d
 
I
L
-
1
β
c
o
n
c
e
n
t
r
a
t
i
o
n
 
(
p
g
/
m
L
)
GBSS
Ad-GFP (5e11 particles/joint)
rAAV2-GFP (5e11 DRP/joint)
scAAV2-GFP (5e11 DRP/joint)
scAAV2-GFP (1e13 DRP/joint)
(e)
∗ ∗
0
0.5
1
2
1.5
2.5
3
L
a
m
e
n
e
s
s
 
g
r
a
d
e
0 7 14 21 28 35 42 49 56
Postinjection days
GBSS
Ad-GFP (5e11 particles/joint)
rAAV2-GFP (5e11 DRP/joint)
scAAV2-GFP (5e11 DRP/joint)
scAAV2-GFP (1e13 DRP/joint)
(f)
Figure 3: In vivo inﬂammatory response of equine metacarpal-phalangeal joints treated by the intra-articular administration of adenoviral
(Ad), recombinant adeno-associated viral (rAAV2), or self-complementary AAV (scAAV2) vectors carrying green ﬂuorescent protein (GFP)
genes. (a) Joint ﬂuid protein concentration, (b) joint ﬂuid white blood cell count, (c) % changes of joint circumference, (d) % changes of
the range of joint motion, (e) joint ﬂuid interleukin-1-beta concentration of the Ad-, rAAV2-, or scAAV2-injected joints, and (f) lameness
grade. ∗Signiﬁcantly greater than all other groups (P<0.04). The Ad-injected joints showed signiﬁcantly greater inﬂammatory responses
compared to the rAAV2/scAAV2-injected joints, although all parameters were returned within normal range in 4-5 weeks after the joint
injection.6 Arthritis
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Figure 4: (a) The titer of neutralizing antibodies (NAb) against adenoviral (Ad), and (b) the titer of NAb against recombinant adeno-
associated viral (rAAV2), or self-complementary AAV (scAAV2) vectors, in the serum, saline- (GBSS) and Ad-injected joint ﬂuid, rAAV-
or scAAV-injected joint ﬂuid, or contralateral uninjected joint ﬂuid. ∗Signiﬁcantly greater than serum Ad/AAV2 NAb titers. There were
no signiﬁcant diﬀerences in NAb titers between types of AAV2 vectors (i.e., rAAV2 versus scAAV2). Both Ad and AAV2 vectors induce the
sustained NAb production in the injected joint ﬂuid and the transient NAb production in the serum and con-tralateral joint ﬂuid.
an intra-articular Ad vector injection is temporary and in
this study was clinically acceptable. The inﬂammation upon
repeat injection was not studied in our report, but may be
greater than ﬁrst injection based on an amnestic immune
response to the Ad vector.
To the authors’ knowledge, this is the ﬁrst study to
report that intra-articularly administered Ad and AAV2
vectors induced antibody production in both serum and
joint ﬂuid. Previously, an intra-articular AAV2 injection has
shown to increase serum antibody in human clinical trial
[23]. The NAb production in the joint ﬂuid may inhibit
the repetitive injections of the gene delivery vectors in the
same joint. A previous study reported that, after intra-artic-
ular IL-1Ra gene transduction by scAAV2 vectors, the rein-
jection of the vectors could not generate detectable levels of
IL-1Raexpression[3].Inthisregard,modiﬁcationofthevec-
tors might be necessary to prevent the immune responses
that might interfere with successful repeat gene therapy ap-
plication,including thecapsidepitopealterationstodecrease
immunogenicity of the vector [24], cross-packaging of
genomes into diﬀerent AAV2 capsid serotype [25], or the ap-
plication of transient immunosuppression at the time of the
second vector administration [26]. Interestingly, the NAb
titers in the Ad- or AAV2-injected joints were greater than
serum titer and remained high (>100 NAb titer) until the
end of the study period, even after the serum Ad or AAV2
titers were faded (Figures 4(a) and 4(b)). This may indicate
the persistence of vectors in the injected joints.
Another important ﬁnding in our study is that, for both
Ad and AAV2 vectors, the NAb titers against Ad/AAV2 vec-
tors were increased in the synovial ﬂuid from not only the
Ad/AAV2-injectedjointbutalsothecontralateraljointwhere
Ad/AAV2 vectors were not administered (Figures 4(a) and
4(b)). The increment and peak of the NAb titer in the
contralateral joints corresponded to the serum NAb titer
suggesting an inﬁltration of Ad antibodies from systemic
circulation into the contralateral joint cavity. This may imply
that treating one joint with viral vector may limit an ef-
ﬁcacy of repeated application of intra-articular gene therapy
in both the previously treated joints and the distant joints, at
least for 6–8 weeks after the initial joint injection. A similar
phenomenon has been noticed with intraocular administra-
tion of AAV2 vectors resulting in systemic antibody pro-
duction and blocked transgene expression upon readmin-
istration in the contralateral eye [27].
Our study supported the safety of intra-articular gene
therapy using AAV vectors in human joints. In this study, the
direct intra-articular administration of relatively high dosage
of rAAV/scAAV vectors (1 × 1013 DRP/joint) did not cause
any detrimental inﬂammatory responses in equine meta-
carpo/tarsophalangeal joints with an average normal syn-
ovial ﬂuid volume of 4.4mL [28]. Osteoarthritis and rheu-
matoid arthritis commonly occur in human knee or elbow
joints with an average normal synovial ﬂuid volume of
4.5mL [29]. In the literature, successful IL-1Ra or marker
gene transductions of the articular cartilage and synovium
were reported by the intra-articular administration of 4.7 ×
1011 particles of rAAV in the mice knee joints [9], 5 × 1011
particlesofscAAVintherabbitkneejoints[3],and1.5×1012
particlesofrAAVintherabbitkneejoints[11].Nosigniﬁcant
inﬂammatory eﬀects were evident in those reports, whereas
the capacities of these rodent joints (0.5mL) were estimatedArthritis 7
to be equal to human metacarpal-phalangeal joints that are a
frequent site of rheumatoid arthritis [3].
5. Conclusion
Our results conﬁrmed our hypothesis that scAAV2 vectors
would show accelerated and greater gene transduction in
vitro compared to rAAV2 and induce less inﬂammation and
immuneresponseinvivocomparedtoAdvectors.Speciﬁcal-
ly, our results conﬁrmed that (1) the scAAV2 vectors can
induce superior gene transduction than rAAV2 in articular
cells, and (2) both rAAV2 and scAAV2 were showed to be
safer vectors for intra-articular administration by induc-
ing signiﬁcantly less joint inﬂammation than Ad vectors.
IncreasedNAbtiterbybothAAV2andAdvectorsmayreduce
eﬀectiveness on repeat joint injection.
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